• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Ikena Oncology, Inc.

Ikena Oncology Reports Second Quarter 2024 Financial Results
August 08, 2024
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
UPDATE – Ikena Oncology Announces Strategic Update
May 28, 2024
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
Ikena Oncology Announces Strategic Update
May 28, 2024
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update
May 13, 2024
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum
April 10, 2024
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
March 12, 2024
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference
February 27, 2024
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer
February 21, 2024
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
Ikena Oncology Outlines Key Priorities and Provides Corporate Updates
January 18, 2024
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results
November 09, 2023
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
Ikena Oncology to Present at Multiple November 2023 Investor Conferences
November 07, 2023
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
Ikena Oncology to Participate in September 2023 Investor Conferences
September 05, 2023
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update
August 10, 2023
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
August 07, 2023
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
Ikena Oncology to Participate in Upcoming Investor Conferences
May 24, 2023
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline
May 15, 2023
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
Ikena Oncology Announces $40 Million Underwritten Offering
May 15, 2023
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days
April 20, 2023
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting
April 17, 2023
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results
March 14, 2023
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting
March 07, 2023
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma
March 06, 2023
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference
February 28, 2023
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
Ikena Oncology Appoints Owen Hughes as Board Chair
December 19, 2022
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update
November 28, 2022
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference
November 22, 2022
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma
November 10, 2022
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
UPDATE -- Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
November 07, 2022
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
November 07, 2022
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance
October 26, 2022
From Ikena Oncology, Inc.
Via GlobeNewswire
Tickers IKNA
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap